ÂÜÀòÂÒÂ×

Tarek Rabah is the current President & CEO of Otsuka North America at Otsuka Pharmaceutical. Prior to this, they served as Vice President, Head of Cardio-Renal Business Unit at AstraZeneca from January 2006 to December 2022. In this role, they were responsible for leading the commercialization of the renal portfolio, including marketing, medical, sales, and market access strategy. Tarek also worked closely with R&D, medical, and regulatory to ensure launch success. Additionally, they managed a $350M budget and 400-person organization with six direct reports. Tarek reported to the EVP of Global Biopharmaceuticals Business Unit.

Prior to AstraZeneca, Tarek Rabah served as Global CVM Japan Desk Head at Novartis Pharma AG from January 1998 to December 2006. In this role, they served as global brand manager and supported the expansion of Japan Cardiovascular and Metabolic (CVM) franchise and launching new products. Tarek also aligned CVM global and local marketing strategy. Tarek advanced franchise sales $850M to #2 market with CVM.

Tarek Rabah earned a MBA from McGill University in Business Administration. Tarek also completed an International Exchange Program from FGV - Fundação Getulio Vargas in Business Administration. Tarek Rabah also holds a BBA from American University of Beirut in Business Administration and a BS from American University of Beirut in Biology. In addition, they have completed the Harvard Leading Enterprise Transformation Programme from Harvard Business School Executive Education.

Some direct reports include Sahil Kirpekar - Head of Business Development, Robert McQuade - EVP & Chief Strategic Officer, Interim Chief Medical Officer, and Angela Colon-Mahoney - VP, People & Business Services.